Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy

Behavioural Pharmacology

Volumn 25, Issue 2, 2014, Pages 137-146

  Smith, Maree T ^a   Lau, Tanya ^a   Wallace, Victoria C J ^b   Wyse, Bruce D ^a   Rice, Andrew S C ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

analgesia; angiotensin II type 2 receptor antagonists; antiretroviral drug induced neuropathy; antiretroviral toxic neuropathy; EMA200; EMA300; HIV associated sensory neuropathy; HIV SN; mechanical hypersensitivity; neuropathic pain

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1 (4 METHOXY 3 METHYLBENZYL) 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; EMA 200; EMA 300; GABAPENTIN; UNCLASSIFIED DRUG; ZALCITABINE; ANALGESIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIRETROVIRAL TOXIC NEUROPATHY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; LATENT PERIOD; MALE; MECHANICAL STIMULATION; NONHUMAN; OPEN FIELD BEHAVIOR; POLYNEUROPATHY; RAT; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; HEAT; HYPERALGESIA; NEURALGIA; POLYNEUROPATHIES; SCIATIC NEUROPATHY; SPRAGUE DAWLEY RAT; TIME; TOUCH; TOXICITY; WISTAR RAT;

ANALGESICS; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HOT TEMPERATURE; HYPERALGESIA; IMIDAZOLES; MALE; NEURALGIA; POLYNEUROPATHIES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SCIATIC NEUROPATHY; TIME FACTORS; TOUCH; ZALCITABINE;

EID: 84896400419     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000025     Document Type: Article

References (45)

1. Anand U, Facer P, Yiangou Y, Sinisi M, Fox M, McCarthy T, et al. (2013). Angiotensin II type 2 receptor (AT(2)R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 17:1012-1026.
2. Begley CG, Hill LM (2012). Raise standards for preclinical cancer research. Nature 483:531-533.
3. Bhangoo SK, Ren D, Miller RJ, Chan DM, Ripsch MS, Weiss C, et al. (2007). CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain Behav Immun 21:581-591.
4. Bhangoo SK, Ripsch MS, Buchanan DJ, Miller RJ, White FA (2009). Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain 5:48.
5. Carli M, Prontera C, Samanin R (1989). Effect of 5-HT1A agonists on stress-induced deficit in open field locomotor activity of rats: evidence that this model identifies anxiolytic-like activity. Neuropharmacology 28:471-476.
6. Cherry CL, Kamerman PR, Bennett DLH, Rice ASC (2012a). HIV-associated sensory neuropathy: still a problem in the post-stavudine era? Future Virology 7:1-6.
7. Cherry CL, Wadley AL, Kamerman PR (2012b). Painful HIV-associated sensory neuropathy. Pain Management 2:43-52.
8. Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, et al. NGX4010 C119 Study Group (2012). A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 59:126-133.
9. Cryan JF, Holmes A (2005). The ascent of mouse: advances in modeling human depression and anxiety. Nat Rev Drug Discov 4:775-790.
10. Dalakas MC (2001). Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6:14-20.
11. Devor M (2009). Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res 196:115-128.
12. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. (2007). Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237-251.
13. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, et al. (2010). Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 67:552-558.
14. Finnerup NB, Sindrup SH, Jensen TS (2010). The evidence for pharmacological treatment of neuropathic pain. Pain 150:573-581.
15. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. (2007). Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-related behavior and the influence of analgesic drugs. Neuroscience 144:1495-1508.
16. Holmes A (2001). Targeted gene mutation approaches to the anxiety-like behavior in mice. Neurosci Biobehav Rev 25:261-273.
17. Huang W, Calvo M, Karu K, Olausen HR, Bathgate G, Okuse K, et al. (2013). A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy. Pain 154:560-575.
18. Hudmon A, Choi JS, Tyrrell L, Black JA, Rush AM, Waxman SG, et al. (2008). Phosphorylation of sodium channel Na(v)1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J Neurosci 28:3190-3201.
19. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ (2002). p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57-68.
20. Kamerman PR, Moss PJ, Weber J, Wallace VC, Rice AS, Huang W (2012). Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J Peripher Nerv Syst 17:19-31.
21. Lee H, Hanes J, Johnson KA (2003). Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711-14719.
22. Maratou K, Wallace VC, Hasnie FS, Okuse K, Hosseini R, Jina N, et al. (2009). Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur J Pain 13:387-398.
23. Martin SW, Butcher AJ, Berrow NS, Richards MW, Paddon RE, Turner DJ, et al. (2006). Phosphorylation sites on calcium channel alpha1 and beta subunits regulate ERK-dependent modulation of neuronal N-type calcium channels. Cell Calcium 39:275-292.
24. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, et al. (2000). Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 69:376-380.
25. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M; The Antiretroviral Cohort Collaboration (2013). Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol [Epub ahead of print].
26. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, et al. (2000). A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54:1080-1088.
27. Miller RJ, Jung H, Bhangoo SK, White FA (2009). Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol 194:417-449.
28. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al.; EuroSIDA study group (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362:22-29.
29. Moller KA, Johansson B, Berge OG (1998). Assessing mechanical allodynia in the rat paw with a new electronic algometer. J Neurosci Methods 84:41-47.
30. Muralidharan A, Wyse BD, Smith MT (2013). Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist, in a rat model of prostate cancer-induced bone pain. Pain Med 15:93-110.
31. Oh JW, Drabik K, Kutsch O, Choi C, Tousson A, Benveniste EN (2011). CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 166:2695-2704.
32. Payne BA, Wilson IJ, Hateley CA, Horvath R, Santibanez-Koref M, Samuels DC, et al. (2011). Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 43:806-810.
33. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS (2010). Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One 5:e14433.
34. Prinz F, Schlange T, Asadullah K (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10:712-713.
35. Rice ASC (2008). Should cannabinoids be used as analgesics for neuropathic pain? Nat Clin Pract Neurol 4:654-655.
36. Rice ASC, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, et al. (2014). A novel target and treatment for post-herpetic neuralgia: EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist studied in a double-blind, placebo-controlled, randomised Phase 2 clinical trial. Lancet (in press).
37. Simpson DM, Brown S, Tobias J (2008). Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70: 2305-2313.
38. 2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Med 14:1557-1568.
39. 2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding and efficacy in rats. Pain Med 14:692-705.
40. Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, Watson K, et al. (2007). Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 8:367-373.
41. Stamboulian S, Choi JS, Ahn HS, Chang YW, Tyrrell L, Black JA, et al. (2010). ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J Neurosci 30:1637-1647.
42. Suzuki R, Kontinen VK, Matthews E, Williams E, Dickenson AH (2000). Enlargement of the receptive field size to low intensity mechanical stimulation in the rat spinal nerve ligation model of neuropathy. Exp Neurol 163:408-413.
43. Wallace VC, Blackbeard J, Pheby T, Segerdahl AR, Davies M, Hasnie F, et al. (2007a). Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 133:47-63.
44. Wallace VC, Blackbeard J, Segerdahl AR, Hasnie F, Pheby T, McMahon SB, Rice AS (2007b). Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain 130:2688-2702.
45. Wallace VC, Segerdahl AR, Blackbeard J, Pheby T, Rice AS (2008). Anxiety-like behavior is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neurosci Lett 448:153-156.